Photoactivation system and method for corneal crosslinking treatment

Photoactivated crosslinking agents using UV light effectively treat corneal ectatic disorders by creating chemical bonds within the cornea, stabilizing and correcting corneal shape changes.

JP7596262B2Active Publication Date: 2024-12-09AVEDRO INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2021519601
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-26
Filing Date
2019-10-09
Publication Date
2024-12-09
Estimated Expiration
2039-10-09

AI Technical Summary

Technical Problem

Corneal ectatic disorders, such as keratoconus and post-LASIK ectasia, result from weakened corneal structures that require effective cross-linking therapy to stabilize and prevent shape changes.

Method used

Systems and methods for photoactivating crosslinking agents, such as riboflavin, using UV light to create chemical bonds within the cornea, employing optical elements and scanning systems to precisely control the light pattern and dosage for targeted crosslinking.

Benefits of technology

Strengthening and stabilizing the cornea, allowing for refractive corrections and addressing conditions like keratoconus and post-LASIK ectasia by enhancing corneal strength and structure.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596262000002
    Figure 0007596262000002
  • Figure 0007596262000003
    Figure 0007596262000003
  • Figure 0007596262000004
    Figure 0007596262000004
Patent Text Reader

Abstract

A system for treating an eye includes a light source configured to provide photoactivating light that photoactivates a crosslinking agent applied to the cornea. The system includes one or more optical elements configured to receive the photoactivating light and generate a beam that defines a spot of photoactivating light. The system includes a scanning system configured to receive the beam of photoactivating light and scan the spot of photoactivating light along a first axis and a second axis to form a scan pattern on the cornea to generate crosslinking activity.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 743,338, filed October 9, 2018, and U.S. Provisional Patent Application No. 62 / 810,497, filed February 26, 2019, which are hereby incorporated by reference in their entireties.

[0002] The present disclosure relates to systems and methods for ocular treatment, and more particularly, to systems and methods for photoactivating crosslinking agents in corneal crosslinking treatments. [Background technology]

[0003] Corneal ectasia disorders, or ectasias, are a group of rare non-inflammatory eye disorders characterized by bilateral thinning of the central, paracentral, or peripheral cornea.

[0004] For example, keratoconus is a degenerative disease of the eye in which structural changes within the cornea weaken it and cause it to deform into an abnormal conical shape. Cross-linking treatments can strengthen and stabilize the areas weakened by keratoconus, preventing the undesirable shape changes.

[0005] For example, a complication known as post-LASIK ectasia can occur due to thinning and weakening of the cornea caused by LASIK (Laser-Assisted in site Keratomileusis) surgery. Post-LASIK ectasia results in a progressive steepening (bulging) of the cornea. Therefore, cross-linking treatment can strengthen and stabilize the structure of the cornea after LASIK surgery and prevent post-LASIK ectasia. Summary of the Invention [Means for solving the problem]

[0006] Embodiments include systems and methods for photoactivating a crosslinking agent in corneal crosslinking treatment.

[0007] According to one exemplary embodiment, a system for treating an eye includes a light source configured to provide photoactivating light to photoactivate a crosslinking agent applied to a cornea. The system includes one or more optical elements configured to receive the photoactivating light and generate a beam that defines a spot of the photoactivating light. The system includes a scanning system configured to receive the beam of photoactivating light and scan the spot of photoactivating light along a first axis and a second axis to form a scan pattern on the cornea to generate crosslinking activity.

[0008] According to another exemplary embodiment, a system for treating an eye includes a light source configured to provide photoactivating light to photoactivate a crosslinking agent applied to a cornea, the system includes one or more optical elements configured to receive the photoactivating light and generate a pattern of the photoactivating light, the system includes a fiber optic element configured to receive the pattern of photoactivating light from the one or more optical elements and transmit the pattern of photoactivating light to the cornea to generate crosslinking activity. [Brief description of the drawings]

[0009] [Figure 1] FIG. 1 illustrates one exemplary system for administering a crosslinking agent and photoactivating light to the cornea of ​​an eye to generate crosslinks in corneal collagen, according to an embodiment of the present disclosure. [Figure 2A] FIG. 1 illustrates an exemplary treatment system in which ultraviolet (UV) light is generated by a light-emitting diode (LED), illuminated onto a digital micromirror device (DMD) using a first set of free-space optics, and projected onto the target tissue using a second set of free-space optics. [Figure 2B] FIG. 2B illustrates one exemplary implementation of the treatment system shown in FIG. 2A. [Figure 3A]FIG. 1 illustrates an exemplary treatment system according to an embodiment of the present disclosure, in which UV light is generated by an LED, projected onto a DMD using a set of free-space optics, and projected onto the target tissue using a flexible coherent fiber bundle. [Figure 3B] FIG. 3B illustrates one exemplary implementation of the treatment system shown in FIG. 3A, according to an embodiment of the present disclosure. [Figure 4A] FIG. 13 illustrates another exemplary treatment system according to an embodiment of the present disclosure, where UV light is generated with an LED that is fiber-coupled to a single optical fiber and is illuminated through a lens onto a DMD, and the resulting UV light pattern is illuminated onto the target tissue using a flexible coherent fiber bundle. [Figure 4B] 4B illustrates one exemplary implementation of the treatment system shown in FIG. 4A according to an embodiment of the present disclosure. [Figure 5A] 1 illustrates yet another exemplary treatment system according to an embodiment of the present disclosure, where UV light is generated by a laser source fiber-coupled into a single optical fiber and projected onto an XY scanning system, and the resulting UV light scanning pattern is projected onto the target tissue using a flexible coherent fiber bundle. [Figure 5B] According to an embodiment of the present disclosure, the XY scanning system of FIG. 5A shows one exemplary pattern that can be scanned on the proximal surface of the coherent fiber bundle to generate a circular treatment pattern on the target tissue. [Figure 5C] According to an embodiment of the present disclosure, the XY scanning system of FIG. 5A shows one exemplary pattern that can be scanned on the proximal surface of the coherent fiber bundle to generate an annular treatment pattern on the target tissue. [Figure 6] 1 illustrates an exemplary approach for optimizing the number of fibers in a coherent fiber bundle for irradiating a target tissue with a UV light pattern, according to an embodiment of the present disclosure. [Figure 7]13 illustrates an alternative treatment system not including a fiber optic element, according to an embodiment of the present disclosure, where UV light is generated by a laser source and projected onto an XY scanning system, and the resulting UV light scanning pattern is projected onto the target tissue. [Figure 8] 1 illustrates an exemplary approach for temporally modulating a spot of UV laser light to spatially adjust the dose of UV light delivered to a target tissue, according to an embodiment of the present disclosure. [Figure 9] 1 illustrates another exemplary treatment system according to an embodiment of the present disclosure, where UV light is generated by a laser source and projected onto an XY scanning system, and the resulting UV light scanning pattern is projected onto the target tissue. [Figure 10] 10 illustrates another exemplary treatment system that modifies the treatment system of FIG. 9 to incorporate diagnostic functionality, according to an embodiment of the present disclosure. [Figure 11] 1 illustrates yet another therapeutic system with diagnostic capabilities, according to an aspect of the present disclosure. [Figure 12A] 1 shows an exemplary graph of a fluorescent signal detected before administration of riboflavin in a cross-linking treatment, according to an aspect of the present disclosure. [Figure 12B] 1 shows an exemplary graph of a fluorescent signal detected after administration of riboflavin in a cross-linking treatment, according to an aspect of the present disclosure. [Figure 12C] 1 shows an exemplary graph of a fluorescent signal detected during irradiation with UV light in a crosslinking treatment, according to an embodiment of the present disclosure. [Figure 13] 13 shows an exemplary graph of signal levels associated with autofluorescence and exogenous fluorescence during different time periods in a crosslinking treatment, according to aspects of the present disclosure. [Figure 14A] 1 illustrates one exemplary scan pattern that may be achieved by an XY scanning system, according to an embodiment of the present disclosure. [Figure 14B] 14B shows an exemplary composite fluorescent image associated with the exemplary scanning pattern of FIG. 14A, according to an embodiment of the present disclosure. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] While the disclosure is susceptible to various modifications and alternative forms, specific embodiments thereof have been shown by way of example in the drawings and will herein be described in detail. It is to be understood, however, that it is not intended to limit the disclosure to the particular forms disclosed, but on the contrary, it is intended to cover all modifications, equivalents, and alternatives falling within the spirit of the disclosure.

[0011] FIG. 1 illustrates an exemplary treatment system 100 for generating collagen cross-linking in a cornea 2 of an eye 1. The treatment system 100 includes an applicator 132 for applying a cross-linking agent 130 to the cornea 2. In an exemplary embodiment, the applicator 132 can be an eye dropper, syringe, or the like that applies the photosensitizer agent 130 as droplets to the cornea 2. Exemplary systems and methods for applying the cross-linking agent are described in U.S. Patent Application No. 10,342,697, filed April 13, 2017, entitled "Systems and Methods for Delivering Drugs to an Eye," the contents of which are incorporated herein by reference in their entirety.

[0012] The cross-linking agent 130 may be provided in a formulation that allows for passage of the cross-linking agent 130 through the corneal epithelium 2a to the underlying region within the corneal stroma 2b. Alternatively, the corneal epithelium 2a may be removed or otherwise incised to allow for more direct application of the cross-linking agent 130 to the underlying tissue.

[0013] The treatment system 100 includes an illumination system that includes a light source 110 and an optical element 112 for directing light to the cornea 2. The light causes photoactivation of the crosslinking agent 130 to produce crosslinking activity in the cornea 2. For example, the crosslinking agent can include riboflavin and the light for photoactivation (hereinafter referred to as photoactivating light) can include ultraviolet A (UVA) (e.g., about 365 nm) light. Alternatively, the photoactivating light can include another wavelength, such as a visible wavelength (e.g., about 452 nm). As will be further described below, corneal crosslinking improves corneal strength by creating chemical bonds in the corneal tissue according to a photochemical dynamic reaction mechanism. For example, riboflavin and photoactivating light can be administered to stabilize and / or strengthen corneal tissue to address corneal ectasia disorders (e.g., keratoconus or post-LASIK ectasia). Furthermore, administration of riboflavin and photoactivated light may enable varying degrees of refractive correction, including, for example, combinations of myopia, hyperopia, astigmatism, irregular astigmatism, presbyopia, and complex corneal refractive surface correction due to corneal ectatic disorders, as well as other conditions such as corneal biomechanical changes / degeneration.

[0014] The treatment system 100 includes one or more controllers 120 that control aspects of the system 100 (including the light source 110 and / or the optical element 112). In one embodiment, the cornea 2 may be more broadly treated with the crosslinking agent 130 (e.g., using eye droppers, a syringe, etc.), and photoactivating light from the light source 110 may be selectively directed to the areas of the cornea 2 to be treated according to a particular pattern.

[0015] The optical element 112 may include one or more mirrors or lenses to direct and focus the photoactivating light emitted by the light source 110 in a particular pattern on the cornea 2. The optical element 112 may further include filters to partially block wavelengths of light emitted by the light source 110 and to select particular wavelengths of light directed to the cornea 2 to photoactivate the crosslinking agent 130. Furthermore, the optical element 112 may include one or more beam splitters to split the beam of light emitted by the light source 110 and may include one or more heat sinks to absorb the light emitted by the light source 110. The optical element 112 may also accurately and precisely focus the photoactivating light to a particular focal plane within the cornea 2 (e.g., at a particular depth within the lower region 2b where crosslinking activity is desired).

[0016] Additionally, the specific characteristics of the photoactivating light may be altered to achieve a desired degree of crosslinking in selected regions of the cornea 2. One or more controllers 120 may control the operation of the light source 110 and / or optics 112 to precisely dispense the photoactivating light according to any combination of wavelength, bandwidth, intensity, power, location, depth of penetration, and / or treatment duration (duration of exposure cycles, duration of dark cycles, and ratio of duration of exposure cycles to dark cycles).

[0017] Parameters for light activation of the cross-linking agent 130 can be adjusted, for example, to reduce the time required to achieve the desired cross-linking. In one implementation, the time can be reduced from minutes to seconds. Some configurations use 5 mW / cm 2 Although the photoactivating light can be applied at an irradiance of 1000 nm to 1000 nm, in order to reduce the time required to achieve the required crosslinking, the photoactivating light can be applied at a greater irradiance (e.g., 5 mW / cm 2 The total dose of energy absorbed by the cornea 2 can be described as the effective dose, which is the amount of energy absorbed through an area of ​​the corneal epithelium 2a. For example, the effective dose for an area of ​​the corneal surface 2a can be, for example, 5 J / cm 2 , or 20 J / cm 2 , or 30 J / cm 2The effective doses listed can be from a single administration of energy or from repeated administrations of energy.

[0018] The optical element 112 of the present treatment system 100 may include a microelectromechanical system (MEMS) device, such as a digital micro-mirror device (DMD), to spatially and temporally modulate the illumination of the photoactivating light. With DMD technology, the photoactivating light from the light source 110 is projected in a precise spatial pattern created by extremely small mirrors arranged in an array on a semiconductor chip. Each mirror represents one or more pixels of the projected light pattern. With the DMD, topograph-guided crosslinking can be performed. Control of the DMD by topography may use several different spatial and temporal irradiance and dose profiles. These spatial and temporal dose profiles can be created using continuous wave illumination, but can be adjusted via pulsed illumination by pulsing the illumination source under varying frequency and duty cycle. Alternatively, the DMD may be adjusted to have different pixel frequencies and duty cycles on a pixel-by-pixel basis to provide ultimate flexibility using continuous wave illumination. Alternatively, both pulsed illumination and a combination of adjusted DMD frequency and duty cycle may be combined. This spatially determined crosslinking may be combined with dosimetry, interferometry, optical coherence tomography (OCT), corneal topography, etc., for pre-treatment planning and / or real-time monitoring and adjustment of corneal crosslinking during treatment. Aspects of the dosimetry system are described in more detail below. Additionally, pre-clinical patient information may be combined with finite element biomechanical computer modeling to generate patient-specific pre-treatment plans. Aspects of the treatment system using the DMD are further described below with reference to Figures 2A and 2B.

[0019] To control the aspect of the projection of the photoactivating light, the embodiment may also employ aspects of multi-photon excitation microscopy. Specifically, rather than irradiating the cornea 2 with a single photon of a particular wavelength, the present treatment system 100 may irradiate multiple photons of longer wavelengths (i.e., lower energy) that combine to initiate cross-linking. Advantageously, longer wavelengths are scattered less in the cornea 2 than shorter wavelengths, which allows longer wavelength light to penetrate the cornea 2 more efficiently than shorter wavelength light. The shadowing effect of incident illumination deeper in the cornea is also reduced compared to conventional short wavelength illumination, because the absorption of light by the photosensitizer is much less at longer wavelengths. This allows for enhanced control over depth-specific cross-linking. For example, in some embodiments, two photons may be used, where each photon carries approximately half the energy required to excite molecules in the cross-linking agent 130 to generate a photochemical reaction, which will be further described below. When the crosslinker molecule absorbs both photons simultaneously, it absorbs enough energy to release reactive radicals in the corneal tissue. Embodiments may also utilize lower energy photons, such that the crosslinker molecule must absorb, for example, 3, 4, or 5 photons simultaneously to release reactive radicals. It is unlikely that multiple photons will be absorbed nearly simultaneously, thus requiring a high flux of excitation photons, which may be provided via a femtosecond laser.

[0020] A number of conditions and parameters affect the cross-linking of corneal collagen by the cross-linking agent 130. For example, the irradiance and dose of the photoactivating light affect the amount and rate of cross-linking.

[0021] When the cross-linking agent 130 is specifically riboflavin, the UVA light may be applied continuously (continuous wave (CW)) or as pulsed light, the choice affecting the amount, rate, and extent of cross-linking. When the UVA light is applied as pulsed light, the duration of the exposure cycle, the dark cycle, and the ratio of the exposure cycle to the dark cycle duration will affect the resulting corneal stiffening. Pulsed light exposure can be used to stiffen the corneal tissue more or less than can be achieved with continuous wave exposure delivering the same amount or dose of energy. Light pulses of appropriate length and frequency can be used to achieve more optimal chemical amplification. For pulsed light treatment, the on / off duty cycle can be between about 1000 / 1 to about 1 / 1000. The irradiance can be about 1 mW / cm2 average irradiance. 2 to about 1000mW / cm 2 and the pulse rate can be between about 0.01 Hz and about 1000 Hz, or between about 1000 Hz and about 100,000 Hz.

[0022] The present therapeutic system 100 may generate pulsed light by employing a DMD (electronically turning the light source 110 on and off) and / or by using mechanical or optoelectronic (e.g., Pockels cell) shutters or mechanical choppers or rotating apertures. Due to the inherent modulation capability of the DMD pixels and the subsequent stiffening based on the modulated frequency, duty cycle, irradiance, and dose delivered to the cornea, complex biomechanical stiffening patterns can be imposed on the cornea. A particular advantage of the DMD system and method is that it allows for the creation of non-periodic, uniform-looking illumination (which eliminates the possibility of inducing photosensitive epileptic seizures or flicker vertigo for pulse frequencies between 2Hz and 84Hz) due to random asynchronous pulse topography patterning.

[0023] Although the exemplary embodiment may use a stepped on / off pulsed light function, it is understood that other functions of applying light to the cornea may be used to achieve a similar effect. For example, light may be applied to the cornea according to a sinusoidal function, a sawtooth function, or other complex functions or curves, or any combination of functions or curves. In fact, it will be understood that the function may be substantially stepped, even though there may be more gradual transitions between the on / off values. Furthermore, it will be understood that the illuminance need not decrease to a value of zero during the off cycle, but may in some cases be above zero during the off cycle. The desired effect may be achieved by applying light to the cornea according to a curve that varies the illuminance between two or more values.

[0024] Examples of systems and methods for delivering photoactivating light are described, for example, in U.S. Patent Application Publication No. 2011 / 0237999, entitled "Systems and Methods for Applying and Monitoring Eye Therapy," filed March 18, 2011, U.S. Patent Application Publication No. 2012 / 0215155, entitled "Systems and Methods for Applying and Monitoring Eye Therapy," filed April 3, 2012, and U.S. Patent Application Publication No. 2013 / 0245536, entitled "Systems and Methods for Corneal Cross-Linking with Pulsed Light," filed March 15, 2013, the contents of which are incorporated herein by reference in their entireties. Embodiments may generate cross-linking activity within the cornea according to a circular and / or annular pattern defined by application of photoactivating light (e.g., via a DMD as described above). Additionally or alternatively, embodiments may generate cross-linking activity within the cornea according to a non-circular and / or non-annular pattern defined by application of photoactivating light (e.g., via a DMD).

[0025] A pattern of photoactivating light can be applied (e.g., via a DMD) to the eye in separate treatment zones with different doses applied sequentially or sequentially. For example, one treatment zone can be "turned off" (i.e., application of the corresponding photoactivating light is stopped) while the other treatment zone can be "left on" (i.e., application of the corresponding photoactivating light continues). The treatment zones can be, for example, annularly shaped around a central point of the eye. There can also be discontinuous zones where the photoactivating light is not applied (e.g., a central treatment zone surrounded by a ring of no light surrounded by an annular treatment zone of light, etc.). The width of the annular zones can be of different dimensions (e.g., one annular zone has a width of 1 mm and another has a width of 2 mm). Applying photoactivating light to annular treatment zones on the periphery of the eye without a central treatment zone can result in hyperopia correction, for example, by increasing the curvature of the central region of the eye while the periphery is strengthened. In some cases, the central and peripheral treatment zones may be elliptical in shape to address astigmatism, for example, by preferentially generating cross-linking activity in areas of the cornea to correct the astigmatism. Such elliptical annular treatment zones are preferentially oriented with the axis of the annular treatment zone aligned according to the orientation of the astigmatism. Elliptical treatment zones may also be irregularly asymmetric (i.e., have major and minor axes that are not perpendicular to each other and may be positioned with separate central points (centroids)).

[0026] The crosslinking treatment may be tailored according to one or more biomechanical properties of the eye, such as corneal topography (i.e., shape), corneal strength (i.e., stiffness), and / or corneal thickness. Optical correction and / or strengthening of the cornea may be achieved by administering the crosslinking agent and / or photoactivating light in one or more iterations (with adjustable properties for each iteration). In general, the treatment plan developed may include multiple applications of the crosslinking agent, the dosage and concentration of the crosslinking agent for each application, the number of applications of the photoactivating light, and the timing, duration, power, energy dosage, and pattern of the photoactivating light for each application. Additionally, the crosslinking treatment may be adapted based on feedback information regarding the biomechanical properties collected in real time during treatment or during interruptions in treatment.

[0027] The addition of oxygen also affects the degree of crosslinking in the cornea. In human tissue, the O2 content is extremely low compared to the atmosphere. However, the rate of crosslinking in the cornea is related to the concentration of O2 when the photoactivating light is applied. Therefore, it may be advantageous to actively increase or decrease the concentration of O2 during irradiation to control the crosslinking rate until the desired degree of crosslinking is achieved. Oxygen may be administered during crosslinking treatment in several different ways. One approach is to supersaturate the riboflavin with O2. In this way, when the riboflavin is administered to the eye, a high concentration of O2 is administered directly into the cornea along with the riboflavin, influencing the reaction involving O2 when the riboflavin is exposed to the photoactivating light. According to another approach, a steady state of O2 (at a selected concentration) is maintained at the surface of the cornea, and the cornea is exposed to a selected amount of O2, allowing O2 to enter the cornea. 1, for example, the treatment system 100 also includes an oxygen source 140 and an oxygen delivery device 142 that optionally delivers oxygen to the cornea 2 at an optionally selected concentration. Exemplary systems and methods for administering oxygen during cross-linking treatment are described, for example, in U.S. Patent No. 8,574,277, entitled "Eye Therapy," filed October 21, 2010, and U.S. Patent No. 9,707,126, entitled "Systems and Methods for Corneal Cross-Linking with Pulsed Light," filed October 31, 2012, the contents of which are incorporated herein by reference in their entireties. Additionally, an exemplary mask device for administering oxygen concentration and photoactivating light in eye treatment is described in U.S. Patent Application Publication No. 2017 / 0156926, entitled "Systems and Methods for Treating an Eye with a Mask Device," filed December 3, 2016, the contents of which are incorporated herein by reference in their entirety. For example, a mask can be placed over the eye to provide a consistent and known oxygen concentration on the surface of the eye.

[0028] Riboflavin undergoes photoactivation upon absorption of radiation energy (particularly light). There are two photochemical kinetic pathways for the photoactivation of riboflavin: Type I and Type II. The reactions involved in both Type I and Type II mechanisms, as well as other aspects of the photochemical kinetic reactions that generate crosslinking activity, are described in U.S. Patent No. 10,350,111, entitled "Systems and Methods for Cross-Linking Treatments of an Eye," filed April 27, 2016, the contents of which are incorporated herein by reference in their entirety.

[0029] As described above, the treatment system 100 includes optical elements 112 that direct light (e.g., UV light) from the light source 110 to photoactivate the crosslinking agent 130 (e.g., riboflavin) applied to the cornea 2, thus generating crosslinking activity. In particular, the photoactivating light can be selectively directed to regions of the cornea 2 according to specific spatial treatment patterns. In some embodiments, the treatment system can provide adjustable treatment patterns such that different ocular conditions can be treated with the same treatment system.

[0030] 2A illustrates an exemplary treatment system 200 that can treat different ocular conditions by providing different treatment patterns. The treatment system 200 includes a light emitting diode (LED) 210a and a homogenizing rod 210b that generates UV light. The treatment system 200 also includes a first set of free space optics 212a that irradiates the UV light onto a DMD 212b. The DMD 212b can spatially modulate the UV light according to a desired treatment pattern by selectively directing the UV light on a pixel-by-pixel basis to a second set of free space optics 212c. The second set of free space optics 212c then projects (i.e., focuses) the pattern of UV light from the DMD 212b as output onto the cornea 2.

[0031] As generally labeled in the figures, a "UV generator" refers to one or more elements that generate UV light. A "UV spatial modulator" refers to one or more elements that spatially modulate UV light to define a UV light pattern. A "UV illuminator" refers to one or more elements that illuminate a UV spatial modulator with UV light from a UV generator. A "UV projector" refers to one or more elements that project the UV light pattern from the UV spatial modulator onto a target tissue. Additionally, as shown in the figures, corneal depth may be measured along the z-axis and a pattern of photoactivating light may be projected in the lateral xy plane.

[0032] In the present treatment system 200, the UV light is manipulated and delivered by free-space (i.e., bulk) optical elements, such as a first set of free-space optical elements 212a and a second set of free-space optical elements 212c. Disadvantageously, precise three-dimensional alignment must be maintained between each free-space optical element to prevent distortion of the desired treatment pattern and loss of power of the UV light. Such alignment must be maintained over time against vibration and / or temperature and / or humidity fluctuations. Such alignment must also be addressed with respect to part-to-part variations between the free-space optical elements. The need to maintain alignment can increase the complexity and / or cost of the system and adversely affect reliability.

[0033] Furthermore, to align the UV light pattern to the desired area of ​​the cornea 2, the present treatment system 200 must allow for three-dimensional adjustment of the output UV light. For example, FIG. 2B shows an exemplary implementation of the treatment system 200, in which the elements 210a-b, 212a-c are assembled in combination with a cart 250, and a subject with a cornea 2 is placed on a bed 260. All optical interfaces between the elements 210a-b, 212a-c are free space (shown as dashed lines in FIG. 2B). The UV light pattern projected by the second set of free space optical elements 212c can be moved in the x, y, and z directions relative to the bed 260 and the cornea 2. To allow for the movement of the output UV light, the set of elements 210a-b, 212a-c moves in the x, y, and z directions correspondingly while maintaining the required alignment between the elements 210a-b, 212a-c. In particular, the elements 210a-b, 212a-c may be assembled on an XYZ motion platform 252 that is movably coupled to a cart 250 and allows the entire assembly to be moved relative to a bed 260. However, the use of the XYZ motion platform 252 may require a larger footprint and add additional complexity to the treatment system 200 as compared to the other treatment systems described below.

[0034] According to an aspect of the present disclosure, the optical elements of the treatment system may use fiber optic elements to avoid some of the disadvantages of the treatment system 200. The use of fiber optic elements may eliminate the need for free space optics and opto-mechanical mounts in the treatment system. Advantageously, the use of optical fibers may reduce the size and footprint of the treatment system, reduce the complexity and cost of design and manufacturing, and increase reliability.

[0035] FIG. 3A shows an exemplary treatment system 300 using fiber optic elements. Similar to the treatment system 200 described above, the treatment system 300 includes an LED 310a and a homogenizing rod 310b for generating UV light. The treatment system 300 also includes a first set of free space optics 312a that irradiates UV light onto a DMD 312b, which generates a desired UV light pattern. However, in contrast to the treatment system 200, the UV light pattern from the DMD 312b is not directed to a second set of free space optics. Instead, the UV light pattern is directed to a flexible coherent fiber bundle 312c. The coherent fiber bundle 312c can then be flexibly routed to extend to a position where it can project the UV light pattern onto the cornea 2. The coherent fiber bundle 312c is assembled from thousands of individual fibers, where a 1:1 relative spatial orientation is maintained between the proximal and distal ends of the coherent fiber bundle 312c. (As used herein, "proximal" generally refers to an upstream location closer to the light source, and "distal" generally refers to a downstream location closer to the target tissue.) For example, the coherent fiber bundle 312c may have between 10,000 and 100,000 or more individual fibers, which are often referred to as pixels.

[0036] The coherent fiber bundle 312c may be used with optical elements (e.g., lenses) coupled to the proximal and / or distal ends of the coherent fiber bundle 312c to aid in receiving and transmitting the UV light pattern. As shown in FIG. 3A, a first lens 312d may be coupled to the proximal end of the coherent fiber bundle 312c to receive the UV light pattern from the DMD 312b. Meanwhile, a second lens 312e may be coupled to the distal end of the coherent fiber bundle 312c to provide a desired size of the UV light pattern at a desired working distance from the treatment system 300 (where the cornea 2 is located).

[0037] FIG. 3B shows an exemplary implementation of the treatment system 300, in which the elements 310a-b, 312a-c are assembled in combination with a cart 350, and a subject with a cornea 2 is placed on a bed 360. Compared to FIG. 2B, FIG. 3B shows how the use of a coherent fiber bundle 312c can improve the implementation of the treatment system. The optical interface between the elements 310a-b, 312a-c is free space (shown as dashed lines in FIG. 3B). The XYZ motion stage 352 is movably coupled to the cart 350, allowing the UV light pattern projected from the treatment system 300 to be moved in the x, y, and z directions relative to the bed 360 and the cornea 2. Since the coherent fiber bundle 312c is flexible, the distal end can be coupled to the XYZ motion stage 352 and can move in the x, y, and z directions, while the proximal end remains in a fixed position relative to the DMD 312b. The XYZ motion stage 352 can be manipulated to align the distal end of the coherent fiber bundle 312c with the cornea 2 and deliver the UV light pattern to the desired area of ​​the cornea 2. Meanwhile, the elements 310a-b, 312a-c as well as the proximal end of the coherent fiber bundle 312c can be placed on the cart 350. Unlike the XYZ motion stage 352, the cart 350 does not move in the x, y, and z directions. Thus, the use of the flexible coherent fiber bundle 312c allows the size, weight, and complexity of the XYZ motion stage 352 to be reduced in contrast to the XYZ motion stage 252 shown in FIG. 2B. Furthermore, the opto-mechanical challenges associated with mounting and aligning the elements 310a-b, 312a-c can be significantly reduced.

[0038] FIG. 4A shows another exemplary treatment system 400 using fiber optic elements. Similar to the treatment system 300 described above, the treatment system 400 includes a DMD 412b that generates a desired UV light pattern. In addition, a flexible coherent fiber bundle 412c receives the UV light pattern from the DMD 412b and projects the UV light pattern onto the cornea 2. Lenses 412d, 412e may be coupled to the proximal and distal ends of the coherent fiber bundle 412c, respectively, to assist in transmitting and receiving the UV light pattern. However, in contrast to the treatment system 300, the treatment system 400 does not use a homogenizing rod to generate UV light by a light source. The treatment system 400 also does not use a first set of free space optical elements to illuminate the UV light onto the DMD 412b. Instead, the treatment system 400 uses a light source 410 that is fiber-coupled to the proximal end of a single flexible optical fiber 412a. The light source may be a UV LED or a UV laser light source (e.g., single mode or multimode). The optical fiber 412a can be flexibly routed to a location close to the DMD 412b. A lens 412f (e.g., a collimating lens, a focusing lens, or a similar optical element) can be placed in optical communication with the distal end of the optical fiber 412a to direct the UV light to the DMD 412b. The lens 412f can be held in place relative to a ceramic ferrule at the end of the fiber, providing inherent centering with a simple and reliable fixture. Alternatively, the lens 412f can be held at a fixed distance away from the distal end of the optical fiber 412a to allow a controlled amount of beam expansion for the UV light before entering the lens 412f. This allows the UV light to be directed to the DMD 412b as a spot whose size can be controlled by selecting the appropriate lens 412f and distance.

[0039] The optical fiber 412a may be a multimode fiber to provide spatial homogenization of the UV light passing through the optical fiber 412a, especially when the light source 410 is an LED or multimode laser source. A larger core size of about 100 μm, 1000 μm, or 2000 μm may provide a greater amount of homogenization while reducing the UV intensity within the optical fiber 412a to reduce the risk of photodegradation. If additional homogenization is required, a partially transmissive mask may be applied to the output of the optical fiber 412a. Alternatively, the DMD 412b may be used to partially attenuate a portion of the UV light to achieve a uniform UV light pattern. The light source 410 may also have integrated optical power control to simplify system integration. If the light source 410 is a single mode laser source rather than a UV LED or multimode laser source, spatial homogenization is not required and the fiber 412a may be a single mode fiber. Various alternative strategies can be used to couple the light source 410 to the optical fiber 412a, such as providing a lensed fiber or directly butt-coupling the optical fiber 412a to a laser emitter.

[0040] FIG. 4B shows one exemplary implementation of the treatment system 400. Here, the elements 410, 412a-d are assembled in combination with a cart 450, and a subject having a cornea 2 is placed on a bed 460. FIG. 4B shows how the use of a fiber-coupled light source 410 can improve the implementation of the treatment system. The optical interface between the elements 410, 412a-c is free space (shown as dashed lines in FIG. 4B). An XYZ motion stage 452 is movably coupled to the cart 450, allowing the UV light pattern projected from the treatment system 400 to be moved in the x, y, and z directions relative to the bed 460 and the cornea 2. The XYZ motion stage 452 can be manipulated to align the distal end of the coherent fiber bundle 412c with the cornea 2 and deliver the UV light pattern to a desired area of ​​the cornea 2. Because the optical fiber 412a is flexible, the distal end of the optical fiber 412a can be coupled to the XYZ motion stage 452, while the proximal end remains in a fixed position relative to the light source 410. Correspondingly, the DMD 412b and the coherent fiber bundle 412c are disposed on the XYZ motion stage 452, while the light source 410 is disposed on the cart 450.

[0041] Alternatively, because the coherent fiber bundle 412c is flexible, a distal end of the coherent fiber bundle 412c can be coupled to an XYZ motion stage 452, while the elements 410, 412a-b and a proximal end of the coherent fiber bundle 412c can be placed on a cart 450. This alternative implementation is similar to the implementation shown in FIG.

[0042] The treatment system 400 provides greater design freedom because it includes both a flexible optical fiber 412a and a flexible coherent fiber bundle 412c. The optical fiber 412a and the coherent fiber bundle 412c allow the elements 410, 412a-d to be positioned on the cart 250 and the XYZ motion stage 452 according to different configurations. This configuration can reduce the size, weight, and complexity of the XYZ motion stage 452. Furthermore, the opto-mechanical challenges associated with mounting and aligning the elements 410, 412a-c can be significantly reduced.

[0043] According to a further aspect of the present disclosure, the optical element may include an XY scanning mirror pair for forming the UV light pattern. The use of the XY scanning mirror may eliminate the need for a DMD or similar spatial filter. Advantageously, by using the XY scanning mirror, embodiments may further reduce the size of the treatment system, reduce the complexity and cost of design and manufacturing, and increase reliability.

[0044] For example, FIG. 5A shows an exemplary treatment system 500 that uses an XY scanning system instead of a DMD. The treatment system 500 includes a UV laser source 510 that is fiber-coupled to a single optical fiber 512a (e.g., a multimode or single mode optical fiber). The treatment system 500 also includes a lens 512f (e.g., a collimating lens, a focusing lens, or a similar optical element) disposed at or near the distal end of the optical fiber 512a. In addition, the treatment system 500 includes a galvanometer pair 512b that functions as an XY scanning system. A UV laser travels through the optical fiber 512a, and the lens 512f generates a UV light beam with a small high-quality spot on the galvanometer pair 512b. The galvanometer pair 512b includes a first mirror that can scan the UV light beam in the x-direction and a second mirror that can scan the UV light beam in the y-direction. The treatment system 500 also includes a coherent fiber bundle 512c. The galvanometer pair 512b scans the UV light beam on the surface at the proximal end of the coherent fiber bundle 512c according to the desired pattern. The coherent fiber bundle 512c then projects the UV light scanning pattern onto the cornea 2 according to the desired treatment pattern. Lenses 512d, 512e may be coupled to the proximal and distal ends, respectively, of the coherent fiber bundle 512c to aid in receiving and transmitting the UV light scanning pattern.

[0045] The practitioner can determine a desired treatment pattern, which is converted into independent mirror drive waveforms that cause the first and second mirrors to scan the UV light beam in the x and y directions, respectively. FIG. 5B shows an exemplary pattern 514a in which the galvanometer pair 512b can scan the proximal surface of the coherent fiber bundle 512c to generate a circular treatment pattern on the cornea 2. FIG. 5C shows an exemplary pattern 514b in which the galvanometer pair 512b can scan the proximal surface of the coherent fiber bundle 512c to generate an annular treatment pattern on the cornea 2. Other scan patterns are possible. The speed of the first and / or second mirrors of the galvanometer pair 512b can be adjusted during the scan to increase or decrease the dwell time on a portion of the scan pattern, thereby adjusting the corresponding dose of UV light applied to that portion of the scan pattern. Furthermore, the entire scan pattern can be continuously displaced in the x and y directions on the distal tip of the fiber bundle in response to eye movements. In this way, the UV light pattern can be kept centered on the desired portion of the cornea 2 during treatment, even if the eye is moving. (This continuous displacement can also be provided by a DMD in the treatment system described above.)

[0046] When a coherent fiber bundle is employed to project a UV light pattern formed by a DMD or an XY scanning system, the UV light pattern is effectively sampled by the individual fibers that define the coherent fiber bundle. If an insufficient number of fibers are used to create the coherent fiber bundle, the UV light pattern projected onto the cornea will be undersampled, which manifests as undesirable quantization. If too many fibers are used to create the coherent fiber bundle, the cost of the coherent fiber bundle will be unnecessarily high. Therefore, it is desirable to optimize the number of fibers in the coherent fiber bundle to achieve the required size and resolution of the UV light pattern projected onto the cornea.

[0047] 6 illustrates an exemplary approach 600 for optimizing the number of fibers in a coherent fiber bundle 612c. As shown in FIG. 6, an exemplary treatment pattern for the cornea is a corneal endoscopic treatment pattern having a diameter D UV A circular area 616a having a length L adj The alignment region 616b is generated with a spatial buffer defined by D. The alignment region 616b provides a spatial buffer within which the UV light pattern can be displaced to accommodate any eye movement. As mentioned above, this displacement can be achieved by a DMD or an XY scanning system. In an exemplary implementation, D UV may be about 10 mm, and L adj can be about 15 mm, resulting in a total area on the cornea with a diameter of about 40 mm. This 40 mm area corresponds to the delivery of UV light from the distal end of the coherent fiber bundle 612c. The fiber bundle is typically a central subset of the total number of fibers. The number of available fibers 613 (also known as "active pixels") is N act Ideally, the entire UV light pattern fills the entire active pixel, so that each fiber 613 (i.e., pixel) in the coherent fiber bundle 612c receives 1 / N of the entire UV light pattern. act Therefore, the diameter of the samples relayed by each pixel is D samp becomes:

number

[0048] 7 shows an alternative treatment system 700 using a UV laser and an XY scanning system without fiber optic elements. The treatment system 700 includes a UV laser source 710 and a lens 712a that references the UV laser into a beam of a desired width. The treatment system 700 also includes an XY scanning system 712b. The beam from the lens 712a illuminates the XY scanning system 712b, which scans the beam directly on the cornea 2 according to the desired treatment pattern.

[0049] In some cases, the Rayleigh range of the beam is long enough that only lens 712a is needed. For example, at a wavelength of 365 nm and a beam waist of 150 μm, the Rayleigh range is 19.4 cm, which provides a sufficient working distance between the treatment system 700 and the cornea 2.

[0050] In other cases, a smaller treatment pattern may be desired. For example, a spot size of 25 μm or 100 μm may be desired for the treatment pattern. In such cases, the Rayleigh length is only 0.5 cm or 8.61 cm, respectively, which does not provide sufficient working distance from the instrument. Therefore, an alternative lens instead of lens 712a can be configured to focus the beam from the laser source 710 to generate the desired spot size on the cornea 2, so that the beam continues to converge from the laser source 710 to the XY scanning system 712b and the cornea 2. If the laser source 710 pre-collimates the laser beam by the nature of its design, a pair of lenses can be used instead of lens 712a to first expand the beam and then focus the beam at the desired working distance. Additionally or alternatively, a scanning lens may be used between the XY scanning system 712b and the cornea 2. The use of such a scanning lens allows the angular spread of the scanning pattern to be converted into a flat scanning pattern, as is commonly done in high numerical aperture laser microscopy applications.

[0051] FIG. 8 illustrates an exemplary approach 800 for temporally modulating a UV laser spot to spatially adjust the dose of UV light applied to the cornea. The UV laser spot may be generated and irradiated on the cornea using an embodiment (e.g., treatment system 500 or 700) comprising a laser source and an XY scanning system as described above. The laser output power may be adjusted in synchronization with the x and y positions of the UV laser spot on the cornea. For example, when the XY scanning system is configured to project the laser spot to a first position on the cornea, the drive current to the laser may be configured at a first level to generate a first output power. Then, when the XY scanning system moves the laser spot to a second position on the cornea, the drive current to the laser may be adjusted to a second level to generate a second output power. Thus, applying a modulated laser drive current synchronized to an XY scanning waveform (e.g., a galvanometer pair mirror drive waveform) allows for pixel-by-pixel adjustment of the UV dose delivered to the cornea. As shown in Figure 8, the amount of UV laser power irradiated at each spot position (1-9) is gradually higher than the previous spot position. The x and y positions are adjusted by applying corresponding drive waveforms to the XY scanning system, as described above. The laser power is adjusted by applying corresponding current drive waveforms to the UV laser source.

[0052] Scanning the UV laser spot, for example as shown in FIG. 8, may also provide photochemical kinetic advantages due to improved oxygen dynamics. As mentioned above, the presence of oxygen also affects the amount of corneal crosslinking. Because the UV laser spot may be stationary or nearly stationary at a given location (x,y) on the cornea for only 10 μs to 100 μs or milliseconds and may not return to the same location (x,y) for milliseconds or hundreds of milliseconds or seconds, the oxygen in the tissue column at location (x,y) has time to be replenished. This may increase the average availability of oxygen in the tissue during the crosslinking treatment, increasing the overall rate and density of crosslink formation.

[0053] It may be advantageous to configure the combination of spot size, laser power, and scanning speed such that aerobic conditions are always present in the volume of tissue irradiated by the UV laser spot at any given time. For example, the scanning speed may be selected such that an area on the cornea having the same size as the UV laser spot is passed by the laser during a certain time T. Next, the laser power may be configured based on the known oxygen consumption rate during corneal crosslinking as a function of the incident laser power such that oxygen is not completely depleted in the irradiated volume of tissue at time T. Finally, the overall scanning frequency F may be configured such that the same area on the cornea is not irradiated by the UV laser spot again until a sufficient amount of oxygen has re-diffused into the corresponding volume of tissue. In this way, the aerobic crosslinking reaction dominates the entire procedure, increasing the efficiency and density of crosslink formation. Advantageously, this allows for aerobic crosslinking at high speeds without the need to supply additional oxygen to the cornea via gas or liquid form. Indeed, the inventors have recently performed experiments showing that this laser-based crosslinking approach can produce cures as good as or better than existing LED-based approaches.

[0054] In contrast to the approach of using a 193 nm wavelength excimer laser following a high intensity pulse regime to produce a photoablative effect on corneal tissue, the UV laser spot used in the above embodiment is configured to avoid the photoablative effect. For example, the laser may have a wavelength of about 365 nm, may be provided in a continuous wave mode or an amplitude modulated mode, but not in a pulsed mode, and the incident power may be well below the photoablative threshold.

[0055] FIG. 9 shows another exemplary treatment system 900 using a UV laser and an XY scanning system. The treatment system 900 includes a UV laser source 910a and a lens 912a. In contrast to the treatment system 700 described above, the treatment system includes a single-mode or multimode optical fiber 910b that transmits the UV light generated by the UV laser source 910a to the lens 912a. The optical fiber 910b provides the additional advantage of allowing the UV laser source 910a to be located anywhere in the system, further reducing the complexity, size, weight, and cost of the XYZ motion stage, for example, as described above. The light emanating from the distal end of the optical fiber 910b is focused using a lens 912a. In particular, the lens 912a is configured to provide a beam that generates a desired focal spot size on the cornea 2 at a desired distance from the lens 912a. Although only a single lens 912a is used as shown in FIG. 9, other embodiments may use additional lenses. The beam from the lens 912a may constantly converge as it moves from the lens 912a to the cornea 2. The treatment system 900 also includes an XY scanning system 912b, which is disposed between the lens 912a and the cornea 2. The beam from the lens 912a illuminates the XY scanning system 912b, which scans the beam directly on the cornea 2 according to the desired treatment pattern as described above.

[0056] FIG. 10 shows another exemplary treatment system 1000 that modifies the above treatment system 900 to incorporate diagnostic functions. Similar to the treatment system 900, the treatment system 1000 includes a UV laser source 1010a and a first lens 1012a. The treatment system 1000 also includes a single-mode or multimode optical fiber 1010b that delivers the UV light generated by the UV laser source 1010a to the first lens 1012a. As FIG. 10 shows, the treatment system 1000 also includes a beam splitter 1014a, which may be a dichroic beam splitter. The beam splitter 1014a is positioned to receive the beam of UV light transmitted by the first lens 1012a. The beam splitter 1014a is configured to transmit a majority (e.g., greater than 90%) of light below a certain selected wavelength close to the wavelength of the UV laser (e.g., less than 390 nm) and reflect a majority of light above the selected wavelength. The treatment system 1000 includes a first photodiode 1014b that can be positioned to receive a first output (i.e., reflected UV light) from the beam splitter 1014a. In particular, the first photodiode 1014b can be used to monitor a portion (e.g., about 10%) of the UV power delivered to the tissue 2. The treatment system 1000 also includes an XY scanning system 1012b that is positioned between the beam splitter 1014a and the cornea 2. The light transmitted by the beam splitter 1014a illuminates the XY scanning system 1012b, which scans the beam directly on the cornea 2 according to a desired treatment pattern.

[0057] As will be further described below, the cornea 2 may emit a fluorescence signal at a point different from the point of crosslinking treatment. The fluorescence signal may be evaluated to assess an aspect of the crosslinking treatment. The fluorescence travels to the XY scanning system 1012b and the beam splitter 1014a (shown as a dotted line in FIG. 10). Because the fluorescence has a wavelength longer than the selected wavelength, the beam splitter 1014a also reflects the fluorescence (rather than transmitting it). Therefore, the present treatment system 1000 includes a second photodiode 1014c (or alternatively, a spectrometer, or a camera) that may be positioned to receive a second output (i.e., the fluorescence) from the beam splitter 1014a. The second photodiode 1014c may be used to monitor the fluorescence emitted by the cornea 2 before, during, and / or after crosslinking activity is generated in the cornea 2. The treatment system 1000 may include a second lens 1014d to improve the coupling efficiency of the fluorescent light to the second photodiode 1014c.

[0058] FIG. 11 shows yet another treatment system 1100 that also incorporates diagnostic capabilities. Similar to the treatment system 1000, the treatment system 1100 includes a UV laser source 1110a and a first lens 1112a. The treatment system 1100 also includes a single-mode or multimode optical fiber 1110b that directs the UV light generated by the UV laser source 1110a to the first lens 1112a. The treatment system 1100 includes a first beam splitter 1114a (e.g., a dichroic beam splitter) and a first photodiode 1114b. The first beam splitter 1114a is positioned to receive the beam of UV light transmitted by the first lens 1112a. The first beam splitter 1114a is configured to transmit most of the light below a selected wavelength close to the wavelength of the UV laser and reflect most of the light above the selected wavelength. The first photodiode 1114b receives the UV light reflected from the first beam splitter 1114a and can be used to monitor the portion of the UV power delivered to the tissue 2. The treatment system 1100 also includes an XY scanning system 1112b. The light transmitted by the first beam splitter 1114a illuminates the XY scanning system 1112b, which scans the beam directly on the cornea 2 according to the desired treatment pattern.

[0059] In contrast to the treatment system 1000, the present treatment system 1100 also includes a second beam splitter 1116a, which may be a dichroic beam splitter. The second beam splitter 1116a is disposed between the XY scanning system 1112b and the cornea 2. The second beam splitter 1116a is configured to transmit a beam from the XY scanning system 1112b to the cornea 2 and to scan the beam on the cornea 2 as desired. The cornea 2 may emit fluorescence, which may be evaluated to assess aspects of the crosslinking treatment. This fluorescence is transmitted to the second beam splitter 1116a (shown as a dotted line in FIG. 11). The second beam splitter 1116a is configured to reflect the fluorescence (rather than transmitting it to the XY scanning system 1112b). The treatment system 1100 includes a second photodiode 1116b (or alternatively, a spectrometer, or a camera) that may be positioned to receive the fluorescence from the second beam splitter 1116a. The second photodiode 1116b may be used to monitor the fluorescence emitted by the cornea 2 before, during, and / or after crosslinking activity is generated in the cornea 2. The treatment system 1100 may include a second lens 1116c to improve the coupling efficiency of the fluorescence to the second photodiode 1116b.

[0060] Advantageously, the location of the second beam splitter 1116a close to the tissue 2 (i.e., between the XY scanning system 1112b and the tissue 2) improves the efficiency of the fluorescence collection by the second photodiode 1116b. This arrangement also allows a larger optical aperture to be used to collect the fluorescence, since it does not first pass through the XY scanning system 1112b. In the treatment system 1000 described above, the size of the mirror of the XY scanning system 1012b may be only a few mm in diameter, which may limit the subsequent collection of the fluorescence at the beam splitter 1014a.

[0061] The above embodiments may also include additional elements (e.g., cameras and fixed light sources) that may aid in the visualization of the eye for alignment and tracking purposes. Such elements may be placed coaxially with the treatment beam by using additional beam splitters. Alternatively, these elements may be placed in an off-axis manner by mounting them outside the path of the UV laser beam. Alternatively, the dichroic beam splitter may be replaced by another optical element (e.g., a trichroic beam splitter, a prism, or a diffraction grating) that allows multiple wavelength bands of fluorescence from the tissue to be spatially separated and captured by multiple photodiodes. This has the added advantage of allowing multiple fluorescent signals, such as fluorescent signals from collagen, nicotinamide adenine dinucleotide (NADH), or other biological materials, to be simultaneously evaluated before, during, or after crosslinking, in addition to the fluorescent signal from the crosslinking agent.

[0062] As shown as example graphs in Figures 12A-C, the detected fluorescence signal may change over time during crosslinking treatment. Before administration of riboflavin, autofluorescence of corneal tissue (e.g., from NADH or collagen) may be present at a low level in the first wavelength band λ1-λ2, as shown in graph 1200a of Figure 12A. After administration of riboflavin, exogenous fluorescence may appear at a high level in the second wavelength band λ2-λ3, while the autofluorescence in the first wavelength band λ1-λ2 remains stable, as shown in graph 1200b of Figure 12B. During application of UV light, autofluorescence in the first wavelength band λ1-λ2 may increase, while exogenous fluorescence in the second wavelength band λ2-λ3 from riboflavin may decrease, as shown in graph 1200c of Figure 12C. At the same time, exogenous fluorescence from products resulting from the decomposition of riboflavin (e.g., lumichrome and lumiflavin) may increase. By collecting fluorescence, embodiments (e.g., treatment systems 1000, 1100) can monitor tissue uptake of riboflavin prior to crosslinking and the progress of crosslinking during exposure to UV light. The fluorescence signal can be spectrally resolved using a spectrometer or integrated over discrete wavelength bands (shown as signal levels P1 and P2 in Figures 12A-C) using appropriate optical filters and photodiodes.

[0063] FIG. 13 shows an exemplary graph 1300 of signal levels associated with autofluorescence in a first wavelength band λ1-λ2 (identified as P1) and exogenous fluorescence in a second wavelength band λ2-λ3 (identified as P2) during different time periods in a crosslinking treatment. Real-time monitoring of signal levels P1 and P2 may be used to guide the crosslinking treatment. During the riboflavin soaking period (shown as T1-T2 in FIG. 13), signal level P2 may be monitored to ensure that sufficient riboflavin is present prior to photoactivation with UV light. For example, if signal level P2 does not reach a pre-determined threshold, the practitioner may be prompted to extend the riboflavin soaking period. During the initial photoactivation period (shown as T2-T3 in FIG. 13), photoactivation of riboflavin may decrease signal level P2, while crosslink formation increases signal level P1. Either direct or ratio measurements of signal levels P1 and P2 over this period may assess the rate of riboflavin consumption and the rate of crosslinking site generation. Such assessment of the rate of riboflavin consumption, the rate of crosslinking site generation, and / or the relative ratio of these two rates can be used to assess the efficiency of the crosslinking treatment. If necessary, the photoactivation parameters (i.e., aspects of the UV light application) can be adjusted in real time to ensure that a sufficient density of crosslinks is formed before the treatment is terminated. For example, the irradiance can be reduced to improve efficiency or the total dose can be increased in real time. During the second photoactivation period (shown as T3-T4 in FIG. 13), the signal levels P1 and P2 can be further monitored to ensure that the desired fluorescent signal reaches an end point.

[0064] In some embodiments, the use of an XY scanning system allows for the measurement of any spatial variations in the relative rates of riboflavin consumption and crosslink formation. Furthermore, the XY scanning system also allows for real-time spatial adjustment of photoactivation parameters to achieve a more optimal treatment. In some cases, the relative ratio of signal levels P1 and P2 may need to be calibrated to account for the fact that riboflavin in collagen may absorb a portion of the autofluorescence associated with signal level P1. Such calibration may include scaling the measured magnitude of signal level P1. This scaling may depend on the magnitude of signal level P1 and may occur in real time.

[0065] By measuring the autofluorescence as a baseline before the start of crosslinking treatment (before administration of riboflavin and photoactivation) and monitoring the signal levels P1 and P2 in real time during crosslinking treatment, the practitioner can determine when substantially all of the riboflavin has been consumed and / or when a more optimal crosslink density has been achieved. Thus, real-time monitoring can be used to determine when the crosslinking treatment should be stopped, e.g., when a desired therapeutic result has been achieved, or when the crosslinking treatment should be paused (e.g., when riboflavin is depleted before the desired therapeutic result is achieved). In the latter case, the crosslinking treatment can be resumed after administering more riboflavin.

[0066] Additionally, changes in peak intensity of autofluorescence (signal level P1) and / or the rate of cross-linking generation can be evaluated to assess local changes in corneal stiffness. Such evaluation of changes in corneal stiffness can be considered in combination with a corneal biomechanical model to assess changes in corneal shape and / or a visual acuity model to assess changes in the patient's visual acuity.

[0067] Thus, monitoring the signal levels P1 and P2 can be used to determine the local rate of change of riboflavin consumption and crosslink formation, respectively. These rates may vary between different eyes and may vary locally in one cornea. Real-time monitoring of these rates during treatment allows the treatment parameters to be adjusted to optimize the treatment outcome. Real-time monitoring allows the practitioner to determine if the concentration of riboflavin has been exhausted or when the crosslinking treatment should be stopped. In general, the treatment parameters can be adjusted to control: (i) the rate of crosslink generation according to a predetermined level; (ii) the change in corneal stiffness according to a predetermined level (which may involve a correlation between the rate of crosslink formation and an increase in corneal stiffness); (iii) the change in corneal shape according to a predetermined treatment outcome (which may involve the use of a corneal biomechanical model to calculate the change in corneal shape induced by the volumetric change in crosslink density); or (iv) the change in visual acuity according to a predetermined treatment outcome (which may involve the use of a corneal biomechanical model and a visual acuity model to calculate the change in the patient's visual acuity induced by the volumetric change in crosslink density).

[0068] Furthermore, the pre-treatment signal level P1 (autofluorescence) can be correlated with the rate of crosslink generation (crosslinking efficiency). Thus, treatment parameters can be titrated prior to the initiation of crosslinking treatment based on pre-treatment measurements of collagen autofluorescence.

[0069] FIG. 14A shows an exemplary scan pattern 1400a that may be achieved by the XY scanning system described above. Since the (x, y) coordinates of the spot of UV light on the cornea are known at each time point, a composite fluorescent image 1400b as shown in FIG. 14B may be generated and presented to the practitioner. The grayscale or color value at each (x, y) coordinate of the composite image 1400b may correspond to signal levels P1 and P2, or the ratio of signal level P1 to signal level P2. For example, signal level P1 may be higher at coordinate (x1, y1) than signal level P2 at coordinate (x2, y2). By presenting the composite fluorescent image 1400b during the riboflavin soak period, the practitioner may understand the spatial distribution of the drug prior to UV light activation. By presenting the composite fluorescent image 1400b during UV light activation, the practitioner may understand the spatial distribution of crosslink formation in order to make subsequent decisions regarding the patient's treatment (e.g., identifying the need for additional treatment).

[0070] As mentioned above, according to some aspects of the present disclosure, some or all of the steps of the procedures described and illustrated above may be automated or guided under the control of a controller (e.g., controller 120). In general, the controller may be implemented as a combination of hardware and software elements. The hardware aspects may include a combination of operatively coupled hardware components including a microprocessor, logic circuitry, communication / network ports, digital filters, memory, or logic circuitry. The controller may be adapted to perform operations specified by computer-executable code, which may be stored on a computer-readable medium.

[0071] As mentioned above, the controller may be a programmable processing device (e.g., an external conventional computer, or an on-board field programmable gate array (FPGA), or digital signal processor (DSP)) that executes software or stored instructions. In general, the physical processor and / or machine used by the embodiments of the present disclosure for any processing or evaluation may include one or more networked or non-networked general-purpose computer systems, microprocessors, field programmable gate arrays (FPGA), digital signal processors (DSP), microcontrollers, etc., programmed according to the teachings of the exemplary embodiments of the present disclosure, as will be understood by those skilled in the computer and software arts. The physical processor and / or machine may be externally networked with the image capture device, or may be integrated to reside within the image capture device. As will be understood by those skilled in the software arts, appropriate software may be readily prepared by a programmer of ordinary skill based on the teachings of the exemplary embodiments. Furthermore, the devices and subsystems of the exemplary embodiments may be implemented by the preparation of application specific integrated circuits or by interconnecting a number of conventional component circuits in an appropriate network, as will be understood by those skilled in the electrical arts. Thus, the exemplary embodiments are not limited to any specific combination of hardware circuitry and / or software.

[0072] Exemplary embodiments of the present disclosure may include software stored on any one or combination of computer readable media for controlling the devices and subsystems of the exemplary embodiments, for driving the devices and subsystems of the exemplary embodiments, and for enabling the devices and subsystems of the exemplary embodiments to interact with a human user or the like. Such software may include, but is not limited to, device drivers, firmware, operating systems, development tools, application software, and the like. Such computer readable media may further include computer program products of the embodiments of the present disclosure for performing all or a portion (if the processing is distributed) of the processing performed in the implementation. Computer code devices of the exemplary embodiments of the present disclosure may include any suitable interpretable or executable code mechanism, including, but not limited to, scripts, interpretable programs, dynamic link libraries (DLLs), Java classes and applets, complete executable programs, and the like. Additionally, portions of the processing of the exemplary embodiments of the present disclosure may be distributed for better performance, reliability, cost, and the like.

[0073] Common forms of computer readable media may include, for example, a floppy disk, a flexible disk, a hard disk, magnetic tape, other suitable magnetic media, CD-ROM, CDRW, DVD, other suitable optical media, punch cards, paper tape, optical mark sheets, other suitable physical media with a pattern of holes or other optically recognizable indicia, RAM, PROM, EPROM, Flash EPROM, other suitable memory chips or cartridges, a computer readable carrier wave, or other suitable medium.

[0074] Although the present disclosure has been described with reference to one or more specific embodiments, those skilled in the art will recognize that many modifications may be made thereto without departing from the spirit and scope of the present disclosure. Each of these embodiments and their obvious variations are considered to be within the spirit and scope of the present disclosure. It is also contemplated that additional embodiments according to aspects of the present disclosure may combine any number of features of any of the embodiments described herein.

Claims

1. 1. A system for treating an eye, comprising: a light source configured to provide photoactivating light to photoactivate the crosslinking agent applied to the cornea; one or more optical elements configured to receive the photoactivating light and to generate a beam that defines a spot of the photoactivating light, one or more optical elements configured to form a scanning pattern defined by a plurality of treatment zones on the cornea to generate crosslinking activity, the plurality of treatment zones including at least a first treatment zone and a second treatment zone, a first dose of photoactivating light is provided in the first treatment zone and a second dose of photoactivating light is provided in the second treatment zone, the first dose being greater than the second dose; a scanning system configured to receive the beam of photoactivating light and scan the spot of photoactivating light along a first axis and a second axis; and a movable fiber optic bundle configured to receive a scan pattern from the scanning system and transmit the scan pattern to the cornea, the fiber optic bundle contained within a circular region having an adjustment region configured to provide a spatial buffer; Equipped with The above system.

2. the scanning system includes a galvanometer pair, the galvanometer pair including a first mirror configured to scan the spot of photoactivating light along the first axis and a second mirror configured to scan the spot of photoactivating light along the second axis; The system of claim 1 .

3. At least one of the light source or the scanning system is operable to spatially adjust a dose of the photoactivating light delivered to each portion of the scan pattern. The system of claim 1 .

4. the scanning system is configured to scan the spot of photoactivating light along the first axis according to a first adjustable speed and to scan the spot of photoactivating light along the second axis according to a second adjustable speed, the first adjustable speed and the second adjustable speed determining a dwell time that the spot of photoactivating light is on a portion of the scan pattern and determining a dose of the photoactivating light delivered for crosslinking activity in the portion of the scan pattern. The system of claim 1 .

5. the light source is operable to adjust a power associated with the beam as the scanning system scans the spot of photoactivating light over a portion of the scan pattern, the portion of the scan pattern receiving a dose of the photoactivating light based on the power associated with the beam. The system of claim 1 .

6. the light source is operable to adjust a power associated with the beam, one or more optical elements are operable to adjust a size of a spot of photoactivating light produced by the beam, and the scanning system is operable to adjust a speed of the spot of photoactivating light over a portion of the scan pattern; At least one of the power associated with the beam, the size of the spot of photoactivating light, and the velocity of the spot of photoactivating light are adjusted to aerobic conditions within the cornea for crosslinking activity. The system of claim 1 .

7. a photodiode configured to receive a portion of the beam of photoactivating light to monitor the power of the beam of photoactivating light. The system of claim 1 .

8. a photodiode configured to receive fluorescent light from the cornea to monitor the crosslinking activity; the photodiode receives fluorescent light from a portion of the scan pattern that corresponds to a position of the spot of the photoactivating light along the first axis and the second axis. The system of claim 1 .

9. a photodiode configured to receive fluorescent light from the cornea to monitor the crosslinking activity; The fluorescence includes autofluorescence from corneal tissue and extrinsic fluorescence resulting from decomposition of the crosslinking agent, The system comprises: receiving from the photodiode a first signal corresponding to the autofluorescence and a second signal corresponding to the exogenous fluorescence; and determining a spatial variation in a relative rate of cross-link consumption and cross-link activity in the cornea based on changes in the first signal and the second signal provided by the photodiode as the spot of photoactivating light is scanned over the scan pattern. a controller configured to: In response to the spatial variations, the light source is operable to adjust a power associated with the beam, one or more optical elements are operable to adjust a size of the spot of photoactivating light produced by the beam, and / or the scanning system is operable to adjust a speed of the spot of photoactivating light over a portion of the scan pattern. The system of claim 1 .

10. one or more beam splitters configured to direct a portion of the beam of photoactivating light to a first photodiode for monitoring the power of the beam of photoactivating light and to direct fluorescence from the cornea to a second photodiode for monitoring crosslinking activity; the one or more beam splitters include a first beam splitter configured to direct a portion of the beam of the photoactivating light to the first photodiode and a second beam splitter configured to direct the fluorescent light from the cornea to the second photodiode. The system of claim 1 .

Citation Information

Patent Citations

  • LASER RADIATION TRANSMISSION METHOD AND APPARATUS

    JP1995506733A

  • Ophthalmic equipment

    JP2003245300A

  • Method and apparatus for treating ocular tissue using a multidisciplinary approach

    JP2013525014A

  • Controlled crosslinking initiation and corneal topography feedback system for directing crosslinking

    JP2014519866A

  • System and method for monitoring time-based delivery of photoactivators or the presence of photoactive markers

    JP2014519914A